SGLT-2 inhibitors in diabetes: a focus on renoprotection
نویسندگان
چکیده
منابع مشابه
Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
INTRODUCTION For people with type 2 diabetes (T2DM) inadequately controlled with oral antidiabetic drugs (OADs), evidence from both randomized controlled trials (RCTs) and real-world studies has demonstrated that treatment intensification with liraglutide offers effective glycemic control, weight reduction, and a lower risk of hypoglycemia compared to treatment intensification with insulin or a...
متن کاملTreatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
New treatments for diabetes are always exciting in the beginning but as experience grows their position in management becomes less certain. This review focuses on DPP4 inhibitors and their place in management of type 2 diabetes. Although hypoglycaemia is rarely an issue, the effectiveness in reduction in blood sugar is greatest at the higher blood sugar levels, hence much of the value of using ...
متن کاملSGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Despite the development of several pharmacological agents over the past decade, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium glucose cotransporter 2 (SGLT2) inhibitors, the management of hyperglycaemia in patients with type 2 diabetes remains challenging. SGLT2 inhibitors are a new class of glucose-lowering agents that have a u...
متن کاملUse of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.
INTRODUCTION Diabetes mellitus is one of the most common chronic diseases in the world, with high morbidity and mortality rates, resulting in a greatly negative socioeconomic impact. Although there are several classes of oral antidiabetic agents, most of the patients are outside the therapeutic goal range. OBJECTIVE To review the use of SGLT-2 inhibitors in the treatment of type 2 diabetes me...
متن کاملEditorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?
Type 2 diabetes is among the most important and prevalent chronic diseases, and any novel therapy that is able to address chronic hyperglycaemia is welcome as another tool for clinicians to help prevent the development of diabetic complications [1]. It is widely recommended that, if lifestyle interventions are inadequate, the first line of drug treatment is metformin, followed by a sulphonylure...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista da Associação Médica Brasileira
سال: 2020
ISSN: 1806-9282,0104-4230
DOI: 10.1590/1806-9282.66.s1.17